Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol for Heart Rate Control in Septic Shock
NCT05389176Unknown
- Sponsor
- Chinese Medical Association
- Start
- Jul 2022
- Primary completion
- Mar 2024
- Modality
- Orthosteric Ligands
01
Overview
Randomised, open-label trial of esmolol in septic shock and tachycardia (3 arms), sponsored by Chinese Medical Association. Primary endpoint: Proportion of patients with heart rate of 70-100 bpm at 96 hours. Status: unknown.
02
Drugs
esmolol
03
Conditions
septic shocktachycardia
Beyond the preview
Go deeper on NCT05389176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05389176.